Skip to content
Screener

NeoGenomics NEO Self-pay — NET REVENUE

Other product segments

Client direct billing
$137.96M+5.2%
Commercial insurance
$36.27M+26.1%
Medicare and other government
$27.43M

Similar metrics at other companies

Surgery Partners, Inc. logo
SGRYSelf-pay — Revenue
$23.5M+7.3%
Community Health Systems logo
CYHSelf Pay Revenue — Revenue
$39M+117%
GeneDx Holdings logo
WGSSelf-pay patients — Total Revenue
$286K+198%
ARD
ARDTSelf-pay and other — Net patient service revenue
$96.13M+4.4%
Hitachi logo
HITSelf Funded Plan Administration Fees — Revenue (Gross)
$4.51M
Hormel Foods logo
HRLShelf-stable — Net Sales
$753.75M-8.4%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Client direct billing$137,956$131,157$269,545$253,195
Commercial insurance36,27328,76667,21153,623
Medicare and other government27,42721,38751,57242,488
Self-pay2059
Total net revenue$201,656$181,330$388,328$349,365

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's self-pay — NET REVENUE?
NeoGenomics (NEO) reported self-pay — NET REVENUE of $0 in Q2 2026.
How has NeoGenomics's self-pay — NET REVENUE changed year-over-year?
NeoGenomics's self-pay — NET REVENUE decreased by 100.0% year-over-year, from $20K to $0.
What is the long-term trend for NeoGenomics's self-pay — NET REVENUE?
Over 3 years (2021 to 2024), NeoGenomics's self-pay — NET REVENUE has grown at a -4.1% compound annual growth rate (CAGR), from $772K to $681K.
What does self-pay — NET REVENUE mean?
This metric represents the total revenue generated from genetic and molecular testing services where the patient or individual is directly responsible for payment rather than a third-party insurer or healthcare provider. It serves as a measure of direct-to-consumer or out-of-pocket demand for specialized diagnostic services. Monitoring this revenue stream helps assess the company's ability to capture market share outside of traditional insurance-reimbursed channels.

Ask your AI about NeoGenomics's self-pay — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude